Xu Y, Shen Z, Wiper D W, Wu M, Morton R E, Elson P, Kennedy A W, Belinson J, Markman M, Casey G
Department of Gynecology and Obstetrics, Cancer Center, Cleveland Clinic Foundation, Ohio 44195, USA.
JAMA. 1998 Aug 26;280(8):719-23. doi: 10.1001/jama.280.8.719.
Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer.
To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases.
A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 (an ovarian cancer biomarker) levels were performed by observers blinded to patient status or group.
The Cleveland Clinic Foundation.
A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias.
Total LPA levels in plasma samples from patients and controls.
Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 micromol/L; range, 1.0-43.1 micromol/L) compared with the healthy control group (mean, 0.6 micromol/L; range, <0.1-6.3 micromol/L) (P<.001). Elevated plasma LPA levels were detected in 9 of 10 patients with stage I ovarian cancer, 24 of 24 patients with stage II, III, and IV ovarian cancer, and 14 of 14 patients with recurrent ovarian cancer. Of 36 patients with other gynecologic cancers, 33 also showed higher LPA levels(mean, 14.9 micromol/L; range, <0.1-63.2 pmol/L), compared with healthy controls (P<.001). Elevated plasma LPA levels were detected in 5 of 48 controls and 4 of 17 patients with benign gynecologic diseases and in no women with breast cancer or leukemia. In comparison, among a subset of patients with ovarian cancer, 28 of 47 had elevated CA125 levels, including 2 of 9 patients with stage I disease.
Plasma LPA levels may represent a potential biomarker for ovarian cancer and other gynecologic cancers. However, these findings are preliminary and require confirmation in larger studies.
溶血磷脂酸（LPA）已被证明可刺激卵巢癌细胞增殖，且存在于卵巢癌患者的腹水中。
确定与健康对照相比，卵巢癌及其他妇科恶性肿瘤患者血浆中LPA水平是否升高，并评估血浆LPA水平升高是否可能是这些疾病的生物标志物。
采用研究测定法测量健康女性和患有不同疾病女性血浆中的总LPA水平。所有LPA测定以及LPA水平与CA125（一种卵巢癌生物标志物）水平的比较均由对患者状态或分组不知情的观察者进行。
克利夫兰诊所基金会。
便利样本包括48名健康对照女性、48名卵巢癌女性、36名其他妇科癌症女性、17名良性妇科疾病女性、11名乳腺癌女性和5名白血病女性。
患者和对照血浆样本中的总LPA水平。
与健康对照组（均值0.6微摩尔/升；范围＜0.1 - 6.3微摩尔/升）相比，卵巢癌组患者的血浆LPA水平显著更高（均值8.6微摩尔/升；范围1.0 - 43.1微摩尔/升）（P＜0.001）。10例I期卵巢癌患者中有9例、24例II、III和IV期卵巢癌患者中有24例以及14例复发性卵巢癌患者中有14例检测到血浆LPA水平升高。在36例其他妇科癌症患者中，33例的LPA水平也高于健康对照（均值14.9微摩尔/升；范围＜0.1 - 63.2皮摩尔/升）（P＜0.001）。48名对照中有5例、17例良性妇科疾病患者中有4例检测到血浆LPA水平升高，而乳腺癌或白血病女性中未检测到。相比之下，在一部分卵巢癌患者中，47例中有28例CA125水平升高，包括9例I期疾病患者中的2例。
血浆LPA水平可能是卵巢癌和其他妇科癌症的潜在生物标志物。然而，这些发现是初步的，需要在更大规模的研究中得到证实。
